Please use this identifier to cite or link to this item:
|Scopus||Web of Science®||Altmetric|
|Title:||Co-targeting AR and HSP90 suppresses prostate cancer cell growth and prevents resistance mechanisms|
|Citation:||Endocrine-Related Cancer, 2015; 22(5):805-818|
|Margaret M Centenera, Sarah L Carter, Joanna L Gillis, Deborah L Marrocco-Tallarigo, Randall H Grose, Wayne D Tilley and Lisa M Butler|
|Abstract:||Persistent androgen receptor (AR) signaling in castration resistant prostate cancer (CRPC) underpins the urgent need for therapeutic strategies that better target this pathway. Combining classes of agents that target different components of AR signaling has the potential to delay resistance and improve patient outcomes. Many proto-oncogenes, including the AR, rely on the molecular chaperone heat shock protein 90 (Hsp90) for functional maturation and stability. In this study, enhanced anti-proliferative activity of the Hsp90 inhibitors 17-AAG and AUY922 in androgen-sensitive and castration-resistant prostate cancer cells was achieved when the agents were used in combination with AR antagonists bicalutamide or enzalutamide. Moreover, significant caspase-dependent cell death was achieved using sub-optimal agent doses that individually have no effect. Expression profiling demonstrated regulation of a broadened set of AR target genes with combined 17-AAG and bicalutamide compared with the respective single agent treatments. This enhanced inhibition of AR signaling was accompanied by impaired chromatin binding and AR nuclear localization. Importantly, expression of the AR variant AR-V7 that is implicated in resistance to AR antagonists was not induced by combination treatment. Likewise, the heat shock response that is typically elicited with therapeutic doses of Hsp90 inhibitors, and is a potential mediator of resistance to these agents, was significantly reduced by combination treatment. In summary, the co-targeting strategy in this study more effectively inhibits AR signaling than targeting AR or HSP90 alone and prevents induction of key resistance mechanisms in prostate cancer cells. These findings merit further evaluation of this therapeutic strategy to prevent CRPC growth.|
|Keywords:||prostate cancer; heat shock protein; androgen receptor; combination|
|Rights:||© 2015 by the Society for Endocrinology.|
|Appears in Collections:||Medicine publications|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.